Retreating Neuroendocrine Tumors With Peptide Radiation Therapy: Is a Second Round Effective?

This was a single-center retrospective observational study spanning nine years. Twenty patients with progressive neuroendocrine tumors who had previously received [177Lu]Lu-DOTA-TATE PRRT and subsequently progressed were retreated with the same therapy. Researchers evaluated progression-free survival, overall survival, toxicity (renal, hepatic, hematological), and prognostic factors associated with outcomes.

Neuroendocrine tumors are relatively rare cancers with limited treatment options, especially after progression on standard therapies. PRRT with Lu-177 DOTATATE has become a valuable treatment, but what happens when patients progress afterward has been a major unanswered question. This study provides real-world evidence that retreatment is viable — giving oncologists and patients another option rather than having to move to less targeted therapies.

PRRT represents one of the most successful applications of peptide-based targeted therapy in oncology. The somatostatin analog peptide DOTATATE acts as a guided delivery vehicle for the radioactive isotope lutetium-177, exploiting the fact that neuroendocrine tumors overexpress somatostatin receptors. As more patients live longer with PRRT, the question of retreatment becomes increasingly important. This study adds to growing evidence supporting retreatment and helps identify which patients are most likely to benefit.

This was a small (n=20), single-center, retrospective study — the lowest tier of clinical evidence for treatment efficacy. Two patients were lost to follow-up. There was no control group, so it's impossible to know how much of the benefit was due to retreatment versus natural disease course. The retrospective design is subject to selection bias — patients selected for retreatment may have had more favorable disease characteristics. Specific dosing protocols and patient selection criteria were not detailed in the abstract.